Status:
ACTIVE_NOT_RECRUITING
The INFLUENCE of Cytoreduction on PRO in EOC
Lead Sponsor:
Haukeland University Hospital
Collaborating Sponsors:
Helse Stavanger HF
Sorlandet Hospital HF
Conditions:
Epithelial Ovarian Cancer
Eligibility:
FEMALE
18-100 years
Brief Summary
Based on an improved understanding of how the extent of successful cytoreduction is influenced both by inherent tumor biological characteristics as well as the aggressiveness of the surgical approach ...
Detailed Description
The patients will be recruited at their follow-up appointment after their surgery. At this consultation the patient will be informed about the final diagnosis and extent of disease and a plan for thei...
Eligibility Criteria
Inclusion
- Epithelial ovarian cancer
- Stage \> II
- ECOG \< II
- Treated with primary surgery followed by chemotherapy
- Willing to participate and to sign the informed consent
Exclusion
- \< 18 years old
- Borderline and non-epithelial ovarian tumors
- Stage \< II
- Advanced ovarian cancer submitted to neoadjuvant chemotherapy
- ECOG 3-4
- Pregnancy
- Severe cardiopulmonary disease
- Patients participating in QoL intervention studies
Key Trial Info
Start Date :
March 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03268876
Start Date
March 3 2021
End Date
December 31 2030
Last Update
October 9 2024
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Haukeland University Hospital
Bergen, Norway, 5021
2
Sørlandet sykehus HF
Kristiansand, Norway
3
Stavanger University Hospital
Stavanger, Norway